SEARCH OUR PRODUCT CATALOG

MAX-RUNX2 Fusion FISH Probe

The MAX-RUNX2 Fusion FISH Probe is used to confirm a fusion of the MAX and RUNX2 genes. The fusion of the MAX and RUNX2 genes has been associated with Head And Neck Squamous Cell Carcinoma . These probes are FISH confirmed on normal peripheral blood in both interphase nuclei and metaphase spreads before shipment. Typical turnaround time for this product is 7-14 days after purchase.

** This product is for in vitro and research use only. This product is not intended for diagnostic use.

Turnaround Time: 7-10 Business Days    Shipping Time: 1-2 Day Expedited Shipping

SKU Test Kits Buffer Dye Color Order Now
MAX-RUNX2-20-ORGR  (Standard Design) 20 (40 μL) 200 μL
MAX-RUNX2-20-RERE 20 (40 μL) 200 μL
MAX-RUNX2-20-REOR 20 (40 μL) 200 μL
MAX-RUNX2-20-REGO 20 (40 μL) 200 μL
MAX-RUNX2-20-REGR 20 (40 μL) 200 μL
MAX-RUNX2-20-REAQ 20 (40 μL) 200 μL
MAX-RUNX2-20-ORRE 20 (40 μL) 200 μL
MAX-RUNX2-20-OROR 20 (40 μL) 200 μL
MAX-RUNX2-20-ORGO 20 (40 μL) 200 μL
MAX-RUNX2-20-ORAQ 20 (40 μL) 200 μL
MAX-RUNX2-20-GORE 20 (40 μL) 200 μL
MAX-RUNX2-20-GOOR 20 (40 μL) 200 μL
MAX-RUNX2-20-GOGO 20 (40 μL) 200 μL
MAX-RUNX2-20-GOGR 20 (40 μL) 200 μL
MAX-RUNX2-20-GOAQ 20 (40 μL) 200 μL
MAX-RUNX2-20-GRRE 20 (40 μL) 200 μL
MAX-RUNX2-20-GROR 20 (40 μL) 200 μL
MAX-RUNX2-20-GRGO 20 (40 μL) 200 μL
MAX-RUNX2-20-GRGR 20 (40 μL) 200 μL
MAX-RUNX2-20-GRAQ 20 (40 μL) 200 μL
MAX-RUNX2-20-AQRE 20 (40 μL) 200 μL
MAX-RUNX2-20-AQOR 20 (40 μL) 200 μL
MAX-RUNX2-20-AQGO 20 (40 μL) 200 μL
MAX-RUNX2-20-AQGR 20 (40 μL) 200 μL
MAX-RUNX2-20-AQAQ 20 (40 μL) 200 μL

RUNX2 Gene Summary

This gene is a member of the RUNX family of transcription factors and encodes a nuclear protein with an Runt DNA-binding domain. This protein is essential for osteoblastic differentiation and skeletal morphogenesis and acts as a scaffold for nucleic acids and regulatory factors involved in skeletal gene expression. The protein can bind DNA both as a monomer or, with more affinity, as a subunit of a heterodimeric complex. Two regions of potential trinucleotide repeat expansions are present in the N-terminal region of the encoded protein, and these and other mutations in this gene have been associated with the bone development disorder cleidocranial dysplasia (CCD). Transcript variants that encode different protein isoforms result from the use of alternate promoters as well as alternate splicing. [provided by RefSeq, Jul 2016]

Gene Name: Runt Related Transcription Factor 2

Chromosome: CHR6: 45296053 -45518819

Locus: 6p21.1

MAX Gene Summary

The protein encoded by this gene is a member of the basic helix-loop-helix leucine zipper (bHLHZ) family of transcription factors. It is able to form homodimers and heterodimers with other family members, which include Mad, Mxi1 and Myc. Myc is an oncoprotein implicated in cell proliferation, differentiation and apoptosis. The homodimers and heterodimers compete for a common DNA target site (the E box) and rearrangement among these dimer forms provides a complex system of transcriptional regulation. Mutations of this gene have been reported to be associated with hereditary pheochromocytoma. A pseudogene of this gene is located on the long arm of chromosome 7. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Aug 2012]

Gene Name: MYC Associated Factor X

Chromosome: CHR14: 65472891 -65569227

Locus: 14q23.3

Gene Diseases

The MAX RUNX2 Fusion has been associated with the following diseases:

Disease Name
Head And Neck Squamous Cell Carcinoma 

FISH Probe Protocols

Protocol, Procedure, or Form Name Last Modified Download

Lineage-specific RUNX2 super-enhancer activates MYC and promotes the development of blastic plasmacytoid dendritic cell neoplasm

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a particularly aggressive acute leukemia. BPDCN patients display significantly higher levels of RUNX2 compared to other leukemia patients, due to the RUNX2 super-enhancers harbored by BPDCN cells. Because MYC translocations are also recurrent abnormalities in BPDCN, the team wanted to determine whether RUNX2 super-enhancers also upregulate MYC expression in these tumors. Empire Genomics' RUNX2 probe was used to detect RUNX2 amplification in a series of BPDCNs. Results demonstrated that RUNX2 super-enhancers are in fact hijacked to activate MYC via t(6,8) in BPDCN.